(B-021) The value of integrating multi-care settings real world data for understanding prostate cancer management

Background: Prostate cancer management involves multiple specialties, however real-world data (RWD) sources often reflect only a single care settings, limiting the ability to assess transition of care (TOC) and its impact on disease progression and outcomes. Integrating oncology and urology data may provide a more comprehensive understanding of patient journeys and treatment patterns.

Objectives: To evaluate an integrated oncology and urology RWD dataset for its ability to capture prostate cancer care across specialties, characterize demographics, disease features, and treatment patterns and assess TOC timing and survival outcomes.

Methods: A retrospective analysis was conducted using ConcertAI’s Prostate Patient360TM (curated EHR+claims) dataset from 2014–2024. Patients with prostate cancer were categorized into urology-only, oncology-only, and integrated (urology+oncology) care settings based on the specialty of the clinical data source(s). Estimated TOC was defined as the time point when care shifted from urology to oncology specialty, and was derived across all settings using claims data, where >80% of claims within a rolling 6-day window originated from oncology. Descriptive analyses compared demographics, clinical characteristics at initial diagnosis, TOC, and real-world overall survival (rwOS) across care settings.

Results: The integrated dataset captured key differences in demographics, disease characteristics, and care transitions across care settings. Integrated had lower comorbidity burden (Charlson 3+: 7%) than oncology (12%) and urology (11%). Urology were more likely to be White (86% vs 73% oncology), more frequent lower baseline PSA ( < 10 ng/mL) (29% vs 21% oncology), and less common higher grade tumors (Gleason grade group 5) and de novo metastatic disease (34% and 30% vs 40% and 35% integrated). TOC was estimated for 39% urology, 38% oncology and 30% integrated patients with median time to transition of 9.1, 10.3 and 12.1 months, respectively. Median rwOS varied by setting, 9.9 years (urology), 6.8 years (oncology) and 6.5 years (integrated).

Conclusions: RWD from urology-only, oncology-only or integrated care settings provides distinct yet complementary perspectives on prostate cancer management. Integrating oncology and urology RWD links early disease detection and localized treatment, care transitions , and long-term outcomes, reducing bias from single setting data. Differences in observed rwOS underscore the imapact of sourcing on outcome assessments. By providing a more complete view of demographics, tumor/clinical features, treatment patterns, and care transitions in later-stage disease, integrated RWD enables more robust research on disease progression, treatment sequencing, and patient care pathways.